Clinical trials: Psychotropic Drugs
Cognitively Healthy Subjects Influenced by Psychoactive Drugs
Cognitive Hyper-performance - Effects of Stimulating Substances in Chess-players
Effects of caffeine, methylphenidate, modafinil and placebo on cognitive performance of chess players in chess games and neuropsychiatric standardized tests.
- Trial name
- CHESS (NCT01834547)
- Testing
- Drugs use: methylphenidate, Drug use: modafinil, caffeine
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- K. Lieb
Major Depressive Disorder
Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03357796
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Healthy
A Study to Evaluate the Pharmacokinetics of Duloxetine in Chinese Han Healthy Subjects
The primary objective of this study is to evaluate the pharmacokinetics of duloxetine hydrochloride tablets in Chinese Han Healthy Subjects.
- Trial name
- NCT00933452
- Testing
- duloxetine
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Psychoactive Substance Use Disorder
Psychoactive Drug Uses Among Medical and Pharmacy Students
Drug addiction to psychoactive substances, widely consumed in France, represents a major public health issue. The three main motivations identified for the consumption of psychostimulants would be self-medication, the party…
- Trial name
- PSYCHO'ACT (NCT05115981)
- Where
- France
- Volunteers
- 1,930 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Depressive Disorder, Treatment-Resistant, Stress Disorders, Post-Traumatic
Ketamine Infusions for PTSD and Treatment-Resistant Depression
The relationship between depression and trauma is well established. Co-occuring depression and post-traumatic stress disorder (PTSD) are associated with more severe symptoms and lower levels of functioning.
- Trial name
- NCT02577250
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Minneapolis Veterans Affairs Medical Center
Driving Under the Influence
Whole Blood-plasma-oral Fluid Ratios of Psychoactive Drugs and Medicines
The aim of this study is to get new information on the whole blood-plasma-oral fluid ratios of psychoactive drugs which are encountered in traffic.
- Trial name
- NCT00650130
- Where
- Finland
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Finnish Institute for Health and Welfare
Hypercapnia, Ventilatory Depression
Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
Opioids can decrease breathing and co-administration of benzodiazepines with opioids can further decrease breathing. It is unknown whether certain other drugs also decrease breathing when co-administered with opioids.
- Trial name
- NCT04310579
- Testing
- Oxycodone and Midazolam, Oxycodone, Paroxetine, and Quetiapine
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Schizophrenia
The Phase I Study of HS-10509 in Chinese Adult Subjects
The study is to evaluate the safety, tolerability, and PK characteristics following single administration of HS-10509 in healthy adults, and multiple administrations of HS-10509 in patients with schizophrenia.
- Trial name
- NCT06301074
- Testing
- HS-10509
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Schizophrenia, Psychotic Disorders
Relative Bioavailability of LY03010 Compared to Listed Drug
This is a randomized, multiple-dose, open-label, parallel-group study. Subjects will undergo screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum
- Trial name
- NCT04922593
- Testing
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Where
- 9 sites in United States
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Sleep Disturbance, Mood Disturbance
Enhancement of Sleep Quality and Mood Following Supplementation With Lemon Balm in an Adult Population (Lemslp)
This study aims to investigate the effect of a 4-week dietary intervention of 300mg encapsulated aqueous lemon balm extract on measures of sleep quality, mood and well-being, alongside relevant biomarkers of circadian rhythms in…
- Trial name
- NCT05422599
- Testing
- Lemon balm
- Where
- United Kingdom
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University of Reading
Healthy
Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion
The current protocol is a pilot study of the effects and possible utility of psilocybin-facilitated experiences for professional religious leaders.
- Trial name
- NCT02243813
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Anorexia Nervosa, Psychotropic Drugs
Drugs Experience for Adolescents With Anorexia
The purpose of this study is to access to the experiences of adolescents, their parents and healthcare professionals regarding psychotropic drugs in anorexia nervosa.
- Conditions
- Anorexia Nervosa, Psychotropic Drugs, Adolescent
- Trial name
- E3P (NCT06211517)
- Testing
- Semi-structured interviews with visual mediations, Semi-structured interviews
- Where
- France
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Major Depressive Disorder
A Study of LY03005 vs Pristiq
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in…
- Trial name
- NCT03733574
- Testing
- LY03005, Pristiq
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Nicotine Withdrawal, Marijuana Dependence
Medications Development for the Treatment of Cannabis Related Disorders
The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.
- Conditions
- Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence, Nicotine Dependence
- Trial name
- MTC (NCT01204723)
- Testing
- Active Aprepitant
- Where
- 2 sites in United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- University of Virginia
Psychotropic Drugs Effects
Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T
The primary goal of this double-blind, placebo-controlled, within-subjects functional neuroimaging study is to examine the extent to which the hypnotic zolpidem decreases brain activity in regions of the brain known to process…
- Trial name
- NCT01747590
- Testing
- Zolpidem, Alprazolam, Caffeine
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mclean Hospital
Staff Attitude, Dementia
Changing Talk Online (CHATO) Study
Objectives AIM 1. Establish acceptability and preliminary efficacy of online CHATO modules through pilot testing with NH staff. AIM 2. Develop and pilot test the data collection tool with consultant and advisory panel input.
- Trial name
- NCT03849937
- Testing
- Changing Talk Online (CHATO)
- Where
- 2 sites in United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- University of Kansas Medical Center
Cognitive Symptom, Depression
Psychotropic Drug Use in the Elderly Living in Nursing Homes and the Influence of a Structured Drug Review
The overall aim of this study is to explore if a structured drug review will change clinical symptoms and the psychotropic drugs prescription rate in the elderly living in nursing homes (participants of the study).
- Conditions
- Cognitive Symptom, Depression, Anxiety, Neuropsychiatric Syndrome
- Trial name
- NCT03736577
- Testing
- Drug reviews with NorGeP-NH
- Where
- Norway
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Ostfold Hospital Trust
Healthy
Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs
To evaluate the corrected QT interval change(automatic-reading) after single oral administration of escitalopram, quetiapine and moxifloxacin versus placebo in healthy Korean Adults.
- Trial name
- NCT01871701
- Testing
- Escitalopram, Quetiapine, Moxifloxacin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Alcohol Consumption, Psychoactive Substance Use
AlcoTail - Implementation of Tailored Interventions
This study aims to investigate the implementation and real-world effects of an intervention for harmful use of alcohol and psychoactive medicinal drugs among hospital inpatients.
- Trial name
- NCT04957628
- Testing
- Harmful alcohol use treatment, Non-prescribed psychoactive medicinal use treatment
- Where
- Norway
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital